Arcutis Biotherapeutics, Inc. (ARQT)
$23.74-$1.13 (-4.54%) Today
Howard G. Welgus - DirectorArcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 14 | 81,666 | $2.08M |
| Grant or award | 19 | 218,371 | |
| Option exercise | 28 | 133,120 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
89 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Terrie Curran - Director | Option exercise | Common Stock | 11,148 | $7.51 | $84K | |
| Terrie Curran - Director | Open-market sale | Common Stock | 11,148 | $25.03 | $279K | |
| Terrie Curran - Director | Option exercise | Common Stock | 27,052 | $8.63 | $233K | |
| Terrie Curran - Director | Open-market sale | Common Stock | 27,052 | $25.03 | $677K | |
| Terrie Curran - Director | Option exercise | Stock Option (right to buy) | 11,148 | $0.00 | - | |
| Terrie Curran - Director | Option exercise | Stock Option (right to buy) | 27,052 | $0.00 | - | |
| Terrie Curran - Director | Option exercise | Common Stock | 1,072 | $7.51 | $8K | |
| Terrie Curran - Director | Open-market sale | Common Stock | 1,072 | $26.04 | $28K | |
| Terrie Curran - Director | Option exercise | Stock Option (right to buy) | 1,072 | $0.00 | - | |
| Patrick Burnett - Officer | Open-market sale | Common Stock | 1,697 | $27.00 | $46K | |
| Howard G. Welgus - Director | Option exercise | Common Stock | 822 | $6.52 | $5K | |
| Howard G. Welgus - Director | Option exercise | Common Stock | 1,019 | $7.51 | $8K | |
| Howard G. Welgus - Director | Option exercise | Common Stock | 2,255 | $8.63 | $19K | |
| Howard G. Welgus - Director | Open-market sale | Common Stock | 4,730 | $26.18 | $124K | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 822 | $0.00 | - | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 1,019 | $0.00 | - | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 2,255 | $0.00 | - | |
| Patrick Burnett - Officer | Option exercise | Common Stock | 8,300 | $3.64 | $30K | |
| Patrick Burnett - Officer | Open-market sale | Common Stock | 8,300 | $26.52 | $220K | |
| Patrick Burnett - Officer | Option exercise | Common Stock | 6,700 | $3.64 | $24K | |
| Patrick Burnett - Officer | Open-market sale | Common Stock | 6,700 | $26.08 | $175K | |
| Patrick Burnett - Officer | Option exercise | Stock Option (right to buy) | 8,300 | $0.00 | - | |
| Patrick Burnett - Officer | Option exercise | Stock Option (right to buy) | 6,700 | $0.00 | - | |
| Patrick Burnett - Officer | Open-market sale | Common Stock | 955 | $26.12 | $25K | |
| Masaru Matsuda - Officer | Open-market sale | Common Stock | 1,230 | $26.12 | $32K | |
 Todd Watanabe - Officer | Open-market sale | Common Stock | 4,375 | $26.12 | $114K | |
| Christopher Peetz - Director | Grant or award | Common Stock | 4,315 | $0.00 | - | |
| Christopher Peetz - Director | Grant or award | Stock Option (right to buy) | 21,486 | $0.00 | - | |
| Christopher Peetz - Director | Grant or award | Stock Option (right to buy) | 13,010 | $0.00 | - | |
| Howard G. Welgus - Director | Option exercise | Common Stock | 822 | $6.52 | $5K | |
| Howard G. Welgus - Director | Option exercise | Common Stock | 1,019 | $7.51 | $8K | |
| Howard G. Welgus - Director | Option exercise | Common Stock | 2,255 | $8.63 | $19K | |
| Howard G. Welgus - Director | Open-market sale | Common Stock | 4,730 | $26.91 | $127K | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 822 | $0.00 | - | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 1,019 | $0.00 | - | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 2,255 | $0.00 | - | |
 Sue-Jean Lin - Director | Open-market sale | Common Stock | 4,946 | $24.38 | $121K | |
| Howard G. Welgus - Director | Option exercise | Common Stock | 2,255 | $8.63 | $19K | |
| Howard G. Welgus - Director | Open-market sale | Common Stock | 4,096 | $24.41 | $100K | |
| Howard G. Welgus - Director | Open-market sale | Common Stock | 635 | $25.67 | $16K | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 822 | $0.00 | - | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 1,019 | $0.00 | - | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 2,255 | $0.00 | - | |
| Howard G. Welgus - Director | Option exercise | Common Stock | 822 | $6.52 | $5K | |
| Howard G. Welgus - Director | Option exercise | Common Stock | 1,019 | $7.51 | $8K | |
| Patrick J. Heron - Director | Grant or award | Common Stock | 5,778 | $0.00 | - | |
| Patrick J. Heron - Director | Grant or award | Stock Option (right to buy) | 16,667 | $0.00 | - | |
| Sue-Jean Lin - Director | Grant or award | Common Stock | 5,778 | $0.00 | - | |
| Sue-Jean Lin - Director | Grant or award | Stock Option (right to buy) | 16,667 | $0.00 | - | |
| Howard G. Welgus - Director | Grant or award | Common Stock | 5,778 | $0.00 | - | |
| Howard G. Welgus - Director | Grant or award | Stock Option (right to buy) | 16,667 | $0.00 | - | |
| Keith R. Leonard - Director | Grant or award | Common Stock | 5,778 | $0.00 | - | |
| Keith R. Leonard - Director | Grant or award | Stock Option (right to buy) | 16,667 | $0.00 | - | |
| Terrie Curran - Director | Grant or award | Common Stock | 5,778 | $0.00 | - | |
| Terrie Curran - Director | Grant or award | Stock Option (right to buy) | 16,667 | $0.00 | - | |
| Amit Munshi - Director | Grant or award | Common Stock | 5,778 | $0.00 | - | |
| Amit Munshi - Director | Grant or award | Stock Option (right to buy) | 16,667 | $0.00 | - | |
| Halley E. Gilbert - Director | Grant or award | Stock Option (right to buy) | 16,667 | $0.00 | - | |
| Halley E. Gilbert - Director | Grant or award | Common Stock | 5,778 | $0.00 | - | |
| Neha Krishnamohan - Director | Grant or award | Common Stock | 5,778 | $0.00 | - | |
| Neha Krishnamohan - Director | Grant or award | Stock Option (right to buy) | 16,667 | $0.00 | - | |
| Latha Vairavan - Officer | Open-market sale | Common Stock | 435 | $21.05 | $9K | |
| Patrick Burnett - Officer | Open-market sale | Common Stock | 222 | $21.05 | $5K | |
| Masaru Matsuda - Officer | Open-market sale | Common Stock | 7,372 | $23.27 | $172K | |
| Masaru Matsuda - Officer | Open-market sale | Common Stock | 884 | $23.61 | $21K | |
| Patrick Burnett - Officer | Open-market sale | Common Stock | 684 | $23.61 | $16K | |
| Latha Vairavan - Officer | Open-market sale | Common Stock | 1,341 | $23.61 | $32K | |
| Todd Watanabe - Officer | Open-market sale | Common Stock | 3,172 | $23.61 | $75K | |
| Howard G. Welgus - Director | Open-market sale | Common Stock | 7,144 | $22.99 | $164K | |
| Howard G. Welgus - Director | Open-market sale | Common Stock | 10,000 | $23.88 | $239K | |
| Keith R. Leonard - Director | Option exercise | Common Stock | 27,052 | $8.63 | $233K | |
| Keith R. Leonard - Director | Option exercise | Common Stock | 12,220 | $7.51 | $92K | |
| Keith R. Leonard - Director | Open-market sale | Common Stock | 39,272 | $25.39 | $997K | |
| Keith R. Leonard - Director | Option exercise | Stock Option (right to buy) | 27,052 | $0.00 | - | |
| Keith R. Leonard - Director | Option exercise | Stock Option (right to buy) | 12,220 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Terrie Curran | Director | 38,200 | $956K | View on EDGAR | |
| Terrie Curran | Director | 1,072 | $28K | View on EDGAR | |
| Patrick Burnett | Officer | 1,697 | $46K | View on EDGAR |
Arcutis Biotherapeutics, Inc. (ARQT) had 21 insider filings in the last 90 days, with the most recent on 2026-08-28. The full record for ARQT runs to 89 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ARQT were filed in the last 90 days. 5 purchases are on record for this company.
14 insider sales of ARQT were filed in the last 90 days, totaling $2.08M.
This page tracks ARQT Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ARQT to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
